KR102731945B1 - 아자인돌릴피리돈 및 디아자인돌릴피리돈 화합물 - Google Patents

아자인돌릴피리돈 및 디아자인돌릴피리돈 화합물 Download PDF

Info

Publication number
KR102731945B1
KR102731945B1 KR1020207006930A KR20207006930A KR102731945B1 KR 102731945 B1 KR102731945 B1 KR 102731945B1 KR 1020207006930 A KR1020207006930 A KR 1020207006930A KR 20207006930 A KR20207006930 A KR 20207006930A KR 102731945 B1 KR102731945 B1 KR 102731945B1
Authority
KR
South Korea
Prior art keywords
pyridin
pyrrolo
trifluoromethyl
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207006930A
Other languages
English (en)
Korean (ko)
Other versions
KR20200043412A (ko
Inventor
요한 린드스트룀
리카르드 포스블롬
프레드릭 람
제니 비크룬트
Original Assignee
스프린트 바이오사이언스 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스프린트 바이오사이언스 아베 filed Critical 스프린트 바이오사이언스 아베
Publication of KR20200043412A publication Critical patent/KR20200043412A/ko
Application granted granted Critical
Publication of KR102731945B1 publication Critical patent/KR102731945B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020207006930A 2017-08-23 2018-08-23 아자인돌릴피리돈 및 디아자인돌릴피리돈 화합물 Active KR102731945B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17187519.8 2017-08-23
EP17187519 2017-08-23
PCT/EP2018/072785 WO2019038384A1 (en) 2017-08-23 2018-08-23 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS

Publications (2)

Publication Number Publication Date
KR20200043412A KR20200043412A (ko) 2020-04-27
KR102731945B1 true KR102731945B1 (ko) 2024-11-18

Family

ID=59686871

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207006930A Active KR102731945B1 (ko) 2017-08-23 2018-08-23 아자인돌릴피리돈 및 디아자인돌릴피리돈 화합물

Country Status (20)

Country Link
US (2) US11498919B2 (https=)
EP (2) EP3672967B1 (https=)
JP (2) JP7199738B2 (https=)
KR (1) KR102731945B1 (https=)
CN (3) CN116589461A (https=)
AU (1) AU2018321135B2 (https=)
CY (1) CY1124818T1 (https=)
DK (1) DK3672967T3 (https=)
ES (1) ES2902346T3 (https=)
HR (1) HRP20211999T1 (https=)
HU (1) HUE057818T2 (https=)
IL (3) IL302355A (https=)
LT (1) LT3672967T (https=)
PL (1) PL3672967T3 (https=)
PT (1) PT3672967T (https=)
RS (1) RS62785B1 (https=)
SI (1) SI3672967T1 (https=)
SM (1) SMT202100718T1 (https=)
TW (2) TW202325708A (https=)
WO (1) WO2019038384A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7199738B2 (ja) * 2017-08-23 2023-01-06 スプリント バイオサイエンス アクティエボラーグ アザインドリルピリドンおよびジアザインドリルピリドン化合物
CA3200038A1 (en) * 2020-11-25 2022-06-02 Deciphera Pharmaceuticals, Llc Anti-viral activity of vps34 inhibitors
WO2022115562A1 (en) 2020-11-25 2022-06-02 Deciphera Pharmaceuticals, Llc Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545660A (ja) 2005-05-20 2008-12-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
WO2010003133A2 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
JP2013525354A (ja) 2010-04-19 2013-06-20 アッヴィ・インコーポレイテッド ピロロピリジン系キナーゼ阻害薬
CN103450152A (zh) 2012-06-04 2013-12-18 济南海乐医药技术开发有限公司 基于吲唑、吲哚或氮杂吲唑、氮杂吲哚的双芳基脲类结构抗肿瘤药物
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154024B (it) * 1982-09-22 1987-01-21 Lepetit Spa Derivati pridinici e procedimento per la loro produzione
AU2011346567A1 (en) 2010-12-21 2013-07-25 Novartis Ag Bi-heteroaryl compounds as Vps34 inhibitors
DK2655375T3 (en) 2010-12-23 2015-03-09 Sanofi Sa PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
AU2015206652A1 (en) 2014-01-14 2016-08-04 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
AU2017219846B2 (en) 2016-02-19 2021-05-13 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
DK3416957T3 (da) 2016-02-19 2020-09-21 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
JP7199738B2 (ja) * 2017-08-23 2023-01-06 スプリント バイオサイエンス アクティエボラーグ アザインドリルピリドンおよびジアザインドリルピリドン化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545660A (ja) 2005-05-20 2008-12-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
WO2010003133A2 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
JP2013525354A (ja) 2010-04-19 2013-06-20 アッヴィ・インコーポレイテッド ピロロピリジン系キナーゼ阻害薬
CN103450152A (zh) 2012-06-04 2013-12-18 济南海乐医药技术开发有限公司 基于吲唑、吲哚或氮杂吲唑、氮杂吲哚的双芳基脲类结构抗肿瘤药物
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof

Also Published As

Publication number Publication date
ES2902346T3 (es) 2022-03-28
CY1124818T1 (el) 2022-11-25
CA3072861A1 (en) 2019-02-28
RU2020110503A (ru) 2021-09-23
SI3672967T1 (sl) 2022-04-29
TWI785101B (zh) 2022-12-01
LT3672967T (lt) 2022-01-10
AU2018321135A1 (en) 2020-04-02
PL3672967T3 (pl) 2022-01-31
RU2020110503A3 (https=) 2021-12-27
RS62785B1 (sr) 2022-01-31
EP3672967A1 (en) 2020-07-01
WO2019038384A1 (en) 2019-02-28
US20210122745A1 (en) 2021-04-29
SMT202100718T1 (it) 2022-03-21
EP3672967B1 (en) 2021-10-06
CN111247144B (zh) 2023-04-28
IL272792B (en) 2022-06-01
IL292482B1 (en) 2023-05-01
DK3672967T3 (da) 2022-01-10
IL272792A (en) 2020-04-30
JP7199738B2 (ja) 2023-01-06
CN116589462A (zh) 2023-08-15
PT3672967T (pt) 2021-12-28
AU2018321135B2 (en) 2023-11-23
IL292482A (en) 2022-06-01
CN116589461A (zh) 2023-08-15
TW201912643A (zh) 2019-04-01
HRP20211999T1 (hr) 2022-04-01
CN111247144A (zh) 2020-06-05
TW202325708A (zh) 2023-07-01
JP2020531487A (ja) 2020-11-05
HUE057818T2 (hu) 2022-06-28
US20230322772A1 (en) 2023-10-12
IL302355A (en) 2023-06-01
JP2023021277A (ja) 2023-02-10
US11498919B2 (en) 2022-11-15
KR20200043412A (ko) 2020-04-27
EP4001278A1 (en) 2022-05-25
IL292482B2 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
AU2021215234B2 (en) 6-Aryl-4-Morpholin-1-Ylpyridone Compounds Useful For The Treatment Of Cancer And Diabetes
AU2018320418B2 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
JP2023021277A (ja) アザインドリルピリドンおよびジアザインドリルピリドン化合物
AU2023258375A1 (en) Pyridylpyridone Compounds
CA3072861C (en) Azaindolylpyridone and diazaindolylpyridone compounds
RU2788659C2 (ru) Азаиндолилпиридоны и диазаиндолилпиридоны
HK40072566A (en) Azaindolylpyridone and diazaindolylpyridone compounds
HK40030347B (en) Azaindolylpyridone and diazaindolylpyridone compounds
CA3015045C (en) 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
HK40079059A (en) Pyridylpyridone compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200309

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210820

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231011

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240926

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241114

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241114

End annual number: 3

Start annual number: 1

PG1601 Publication of registration